Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer’s disease
- 86 Downloads
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques (senile plaques) and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein. This process leads to neuronal degradation and neuronal death. Phosphorylation of tau protein at threonine 231 (p-tau231) has been shown to be characteristic in post-mortem brain tissue of patients with AD and it can be sensitively detected in cerebrospinal fluid (CSF). Therefore, it may serve as a biomarker to support the diagnosis of AD. In this study, we analysed how well p-tau231 could differentiate between patients suffering from dementia either due or not due to AD by a sandwich enzyme immunoassay. CSF p-tau231 was significantly higher in patients with dementia due to AD than in those with dementia due to other causes. In addition, we studied different factors affecting p-tau231 levels in CSF. We found that apolipoprotein E genotype influences p-tau231 CSF levels. Gender and age did not affect p-tau231 levels in CSF. Our findings indicate that p-tau231 levels in CSF can be a valuable marker for the clinical diagnosis of AD.
KeywordsBiomarker Alzheimer’s disease CSF p-Tau231
We thank Ulrike Heinze and Anke Jahn-Brodmann for the processing of biomaterial and their support with the assay performance and Prof. Dr. Oliver Wirths for performing the ApoE genotyping. Prof. Jens Wiltfang is supported by an Ilídio Pinho professorship. This study has been supported by the following grants from Instituto de Biomedicina (iBiMED) UID/BIM/04501/2013 and PTDC/DTP_PIC/5587/2014, Fundação para a Ciência e Tecnologia of the Ministério da Educação e Ciência, COMPETE program, the QREN and the European Union (Fundo Europeu de Desenvolvimento Regional).
Compliance with ethical standards
Conflict of interest
IL and KW are employees of AJ Roboscreen GmbH. All other authors declare no conflict of interests.
All procedures performed in studies involving human participants are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
All individual participants gave their informed consent prior to the inclusion into this study.
- Davies P, Resnick J, Resnick B et al (1998) Consensus report of the working group on: “Molecular and biochemical markers of Alzheimer’s disease.” In: Neurobiology of Aging. pp 109–116Google Scholar
- Deuschl G, Maier WS (2017) S3-Leitlinie “Demenzen”, http://www.dgn.org/leitlinien, posted 25 Januar 2016, Accessed 29 November 2017. In: Deuschl G, Maier W S3-leitlin. Demenzen. Dtsch. Gesellschaft für Neurol. Hrsg. Leitlinien für Diagnostik und Ther. der Neurol. http://tinyurl.com/hkwk6lf. Accessed 29 Nov 2017
- Klafki H-W, Hafermann H, Bauer C et al (2016) Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-β peptides in human cerebrospinal fluid and application to a clinical cohort. J Alzheimer’s Dis 54:691–705. https://doi.org/10.3233/JAD-160398 CrossRefGoogle Scholar
- McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005 CrossRefGoogle Scholar
- Shahpasand-Kroner H, Klafki H, Bauer C et al (2018) A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease. Alzheimers Res Ther 10:121. https://doi.org/10.1186/s13195-018-0448-x CrossRefGoogle Scholar
- Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R et al (2018) Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease. Exp Brain Res 236:1241–1250. https://doi.org/10.1007/s00221-018-5210-x CrossRefGoogle Scholar